^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Squamous Non-Small Cell Cancer

    Related cancers:
    1d
    A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=218, Suspended, Sandoz | N=720 --> 218
    Enrollment change
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin
    1d
    eVOLVE-Lung02: A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P3, N=1200, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • PD-L1 negative • ROS1 rearrangement
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • volrustomig (MEDI5752)
    1d
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=430, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Trial completion date: Aug 2031 --> Sep 2030 | Trial primary completion date: Aug 2031 --> Sep 2030
    Enrollment open • Trial completion date • Trial primary completion date • Adverse events
    |
    telisotuzumab adizutecan (ABBV-400)
    2d
    KisMET-01: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=227, Terminated, Mythic Therapeutics | Trial completion date: Dec 2027 --> Nov 2025 | Recruiting --> Terminated; Business decision
    Trial completion date • Trial termination
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET mutation
    |
    MYTX-011
    2d
    A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (clinicaltrials.gov)
    P1/2, N=190, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • patritumab deruxtecan (U3-1402) • Jiataile (sacituzumab tirumotecan) • calderasib (MK-1084)
    2d
    Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=90, Enrolling by invitation, Biogenea Pharmaceuticals Ltd.
    New P1 trial • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    2d
    BRIDGE: Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC (clinicaltrials.gov)
    P2, N=10, Terminated, Mario Negri Institute for Pharmacological Research | Trial completion date: Jun 2026 --> Jan 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jan 2025; Low enrolment rate
    Trial completion date • Trial termination • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • vinorelbine tartrate
    7d
    TTF-1 expression is associated with survival in patients with non-squamous non-small cell lung cancer treated with immune checkpoint inhibitor therapy. (PubMed, Mol Clin Oncol)
    Subset analysis showed that the TTF-1-positive group exhibited significantly longer PFS than the negative group in both the ICI monotherapy (median PFS, 17.6 months vs. 2.9 months, P<0.001, log-rank test) and chemoimmunotherapy (median PFS, 10.4 months vs. 5.2 months, P=0.021, log-rank test) groups. In conclusion, the current study observed an association between TTF-1 expression evaluated using a cocktail antibody and the effectiveness of treatment with ICI monotherapy or chemoimmunotherapy.
    Journal • Checkpoint inhibition • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TTF1 (Transcription Termination Factor 1) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
    |
    EGFR wild-type • ALK wild-type
    7d
    A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer. (PubMed, Future Oncol)
    TACTI-004 will evaluate whether efti can mitigate resistance to ICIs when added to SoC in NSCLC, irrespective of PD-L1 tumor status. www.clinicaltrials.gov identifier is NCT06726265.
    P3 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • PD-L1 underexpression
    |
    Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
    8d
    Docetaxel and Gemcitabine Modulate Cellular Effects and Long Non-Coding RNA Profiles in Non-Small Cell Lung Cancer. (PubMed, Int J Mol Sci)
    According to the European Society for Medical Oncology guidelines for non-oncogene-addicted metastatic non-small-cell lung cancer (NSCLC), patients with metastatic squamous-cell carcinoma (LUSC) or metastatic non-squamous NSCLC with performance status 2 and PD-L1 < 50% may receive single-agent chemotherapy with gemcitabine (GEM), docetaxel (DOC), or vinorelbine. Analysis of three key long non-coding RNAs (lncRNAs)-MALAT1, NEAT1, and HOTAIR-showed variable expression in the studied cell lines as a potential response to DOC and GEM treatment. Our findings indicate different cellular effects of GEM and DOC in NSCLC cell lines and provide an overview of how currently used chemotherapeutics may influence the expression of lncRNAs.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • HOTAIR (HOX Transcript Antisense RNA)
    |
    gemcitabine • docetaxel • vinorelbine tartrate
    8d
    HYPERBOLIC: Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial (clinicaltrials.gov)
    P2, N=74, Not yet recruiting, Università Vita-Salute San Raffaele
    New P2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc)
    8d
    A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=161, Completed, Takeda | N=109 --> 161
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK rearrangement • ALK fusion
    |
    Keytruda (pembrolizumab) • subasumstat (TAK-981)